Published in Law and Health Weekly, September 17th, 2005
"During the third quarter we laid the foundation to become the dominant player in the treatment of atrial fibrillation, with two product launches, both critical to our mission," said Steve Arless, president and CEO of CryoCath. "The accelerated growth and levels in our most important business metrics - sales, disposable units sold, new accounts, and gross margin - provide strong evidence that CryoCath and cryoablation are nearing the critical mass that will support future profitability."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly